Clene Inc., a biopharmaceutical company focused on neurodegenerative diseases, announced a $7 million underwritten offering of 1 million common shares at $7 each to a single investor. The funds will support general corporate expenses and advance the development of their lead drug candidate CNM-Au8®, including NDA preparation, ongoing and future clinical trials, manufacturing expansion, and early-stage research. The offering is expected to close around May 6, 2026. This capital raise is crucial for Clene's efforts to bring new treatments for diseases like ALS and multiple sclerosis to market.
Investec Bank plc, acting as a joint broker for Gamma Communications Plc, disclosed a public dealing on July 27, 2026, involving the purchase and sale of 96,419 ordinary shares of Gamma Communications. The transactions were executed at prices ranging...
Investec Bank plc, acting as advisor and broker for Gooch & Housego plc, disclosed public dealings under the Takeover Code on July 27, 2026. The bank purchased 8,073 ordinary shares at prices between 1220 and 1230 pence and sold 6,000 shares at price...
Alstom and its partners have finalized financing for the Haifa-Nazareth light rail project in Israel, valued at around €2 billion, with Alstom's share at approximately €750 million. The 41-kilometer line will connect Haifa, Nazareth, and nearby commu...
Alstom and its consortium partners have reached financial close for the Haifa-Nazareth light rail project in Israel, a major step enabling full-scale execution. The €2 billion project will build a 41-kilometer light rail line connecting Haifa, Nazare...
The global strategy consulting market, valued at $81.51 billion in 2025, is projected to grow to $194.56 billion by 2035 with a CAGR of 9.09%. Growth is fueled by increasing demand for digital transformation, AI-powered advisory services, ESG consult...
